ABCB1 and neoplasm: The effect of ABCB1 expression on OS remained significant in the IHC (HR, 1.63; 95% CI: 1.22–2.19), the PCR (HR, 1.42; 95% CI: 1.08–1.88), the FIGO III-IV (HR, 1.92; 95% CI: 1.20–3.07), the ABCB1 expression in recurrent tumor (HR, 3.09; 95% CI: 1.79–5.34), the platinum-based non-taxane-containing chemotherapy (HR, 2.55; 95% CI: 1.60–4.05), the America (HR, 1.68; 95% CI: 1.16–2.44) and the Europe (HR, 2.55; 95% CI: 1.57–4.13) subgroups.